Our model, which used a combination of seven markers, including EGFR oncogenic mutation, KRAS oncogenic mutation, PD-L2 gain, PD-L1 gain, MDM2 gain, chr.1q amplification, and chr.20q amplification, showed good performance to associate PD-L1 expression (TPS = 50% cutoff for clone 22C3) in ADC patients. This evidence concerns the gene PDCD1LG2 and AIDS dementia complex.